Tokyo, June 17 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061930) titled 'Study on interindividual variability in pharmacokinetics, pharmacodynamics and tolerability of orexin receptor antagonists in patients with cancer' on June 16.
Study Type:
Observational
Primary Sponsor:
Institute - Shinshu University
Condition:
Condition - Insomnia in patients with cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - The aim of this study is to explore the interindividual variability in pharmacokinetics, clinical effects on sleep-related symptoms, and tolerability of orexin receptor antagonists in patients with cancer, focusing on cancer cachexia, inflammatory cytokines, CYP3A activity, genetic polymorphisms, and concomitant medications.
Basic objectives2 - Pharmacokinetics
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1. Patients aged 18 years or older with a confirmed diagnosis of solid cancer
2. Patients treated with orexin receptor antagonists
3. Patients treated in the outpatient or inpatient setting at Shinshu University Hospital
4. Patients from whom written informed consent was obtained
Key exclusion criteria - 1. Patients using orexin receptor antagonists on an as-needed basis
2. Patients considered not to have reached steady-state plasma concentrations of orexin receptor antagonists
3. Patients who have undergone hematopoietic stem cell transplantation
4. Patients judged by the principal investigator to be inappropriate for the study
Target Size - 200
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2022 Year 07 Month 29 Day
Date of IRB - 2022 Year 09 Month 01 Day
Anticipated trial start date - 2022 Year 09 Month 10 Day
Last follow-up date - 2026 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070853
Disclaimer: Curated by HT Syndication.